A nurse has just administered the morning dose of a patient's lispro (Humalog) insulin.

Just after the injection, the dietary department calls to inform the patient care unit that breakfast trays will be 45 minutes late.
What will the nurse do next?

Choice A rationale

Ensuring the correct medication is given to the right patient is the primary safety priority in medication administration. This fundamental step, part of the "rights" of medication administration, prevents life-threatening errors, such as administering a medication the patient is allergic to or one that is contraindicated for their medical condition.

Choice B rationale

Checking the expiration date is a crucial step to ensure medication efficacy and safety, but it is secondary to patient and medication identification. An expired drug may be ineffective or harmful, but giving the wrong drug to the wrong patient poses an immediate and direct threat to life.

Choice C rationale

Confirming a patient's insurance coverage is an administrative task that has no bearing on the immediate safety or medical necessity of administering the medication. This is a non-clinical function that should not delay or interfere with timely and safe patient care.

Choice D rationale

Documentation of medication administration should always occur after the medication has been given to the patient. Documenting beforehand is an unsafe practice as it can lead to charting errors, such as documenting a medication that was never actually administered, which can endanger the patient.

Choice A rationale

Insulin glulisine is a rapid-acting insulin analog. Its onset of action is typically 10 to 15 minutes, with a peak effect in about one hour. This makes it suitable for use immediately before or with a meal to manage the postprandial glucose spike, but it does not provide the prolonged glucose-lowering effect characteristic of long-acting insulins.

Choice B rationale

Insulin isophane suspension, also known as NPH insulin, is an intermediate-acting insulin. It has a slower onset of action than rapid or short-acting insulins and provides glucose control for a longer duration, typically up to 18 hours. However, its duration is shorter than that of true long-acting insulins, and it has a distinct peak effect.

Choice C rationale

Insulin detemir is a long-acting insulin analog. It is designed to provide a steady, peakless, and prolonged glucose-lowering effect for up to 24 hours. Its mechanism involves binding to albumin in the bloodstream, which slows its absorption and breakdown, ensuring a continuous and stable basal insulin level.

Choice D rationale

Insulin aspart is a rapid-acting insulin analog. Similar to insulin glulisine, it has a rapid onset of action, typically within 10 to 20 minutes, and a peak effect around one to three hours. It is used to cover the glucose increase from meals and is not an example of a long-acting insulin, which provides basal coverage.